PARSIPPANY, N.J. – The Contour Next Link 2.4 Blood Glucose Monitoring System has been cleared by the U.S. Food and Drug Administration and is now available to diabetes patients as part of the Medtronic MiniMed 630G system with SmartGuard technology. Introduced by Ascensia Diabetes Care, a new business unit created this year when Panasonic Healthcare Holdings acquired Bayer Diabetes Care, the Contour Next Link 2.4 is a fingerstick glucometer that sends data wirelessly to Medtronic’s MiniMed 630G insulin pump. The MiniMed630G’s SmartGuard technology triggers an alarm when glucose level reaches a preset low threshold and suspends insulin delivery automatically if the user is unresponsive to the alarm. The Contour is the only FDA-cleared glucometer that connects to a pump. Ascensia renewed its alliance with Medtronic in June to develop and market innovative diabetes management solutions for patients worldwide.
You are here: / / Ascensia’s new glucometer clears FDA